QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.26.2    
  


 
 

2nd AMENDMENT TO THE DISTRIBUTION AGREEMENT    
  


        This Second Amendment to the Distribution Agreement ("AGREEMENT"), is entered into as of October 8, 1999 by and between MedImmune, Inc., a Delaware
Corporation, having its principal place of business at 35 West Watkins Mill Road, Gaithersburg, MD 20878 ("MEDIMMUNE") and Abbott International, Ltd., a Delaware Corporation, having its
principal place of business at 200 Abbott Park Road, Abbot Park, IL 60064. 


WITNESSETH  


        WHEREAS, MEDIMMUNE and Abbott International, Ltd. entered into a Distribution Agreement as of December 1, 1997 that was subsequently amended on
April 28, 1999 (Distribution Agreement and Amendment collectively the "DISTRIBUTION AGREEMENT"). 



        WHEREAS,
the parties desire to further amend the DISTRIBUTION AGREEMENT; 


        1.    DEFINITIONS    



	1.1
	All
fully capitalized terms used in this AGREEMENT have the same meaning as in the DISTRIBUTION AGREEMENT, except as otherwise defined above. 




        2.    AMENDMENT    



	2.1
	Section 3.3.(a)(iii) is
deleted in its entirety and replaced with the following: 



(a)  The
minimum price ("MINIMUM PRICE") for the PRODUCT shall be the greater of I) (CONFIDENTIAL TREATMENT REQUESTED) per vial for the 100mg vials and (CONFIDENTIAL TREATMENT
REQUESTED) per vial for the 50mg vials (CONFIDENTIAL TREATMENT REQUESTED) for the corresponding PRODUCT or ii) (CONFIDENTIAL TREATMENT REQUESTED). If in any quarter of a CONTRACT YEAR, the
MINIMUM PRICE is greater than the price paid for the PRODUCT, then MEDIMMUNE shall notify ABBOTT and ABBOTT shall pay to MEDIMMUNE the difference between the MINIMUM PRICE and the price paid. In
addition, the MIMIMUM PRICE shall be reset for shipments in subsequent quarters to (CONFIDENTIAL TREATMENT REQUESTED). In the event that this paragraph 3.3.(a)(iii) becomes applicable
and this AGREEMENT is no longer economically viable to ABBOTT, then the parties shall discuss a change in PRODUCT pricing. 



	2.2
	Section 3.3.(a)(i) is
deleted in its entirety and replaced with the following: 





No
earlier than the date of delivery to the carrier, MEDIMMUNE may invoice ABBOTT in U.S. Dollars as set forth in subsections 3.3(i)(A-C) below, with payment being made within
forty-five (45) days of invoice, and MEDIMMUNE shall include with such invoice (CONFIDENTIAL TREATMENT REQUESTED) on, respectively, the 100mg vial size and the 50mg vial size. 



	2.3
	The
following shall be added as new Section 3.3 (j): 





MEDIMMUNE
shall keep, and shall cause each of its AFFILIATES to keep full and accurate books of account containing all particulars that may be necessary for the purpose of calculating (CONFIDENTIAL
TREATMENT REQUESTED). Such books of account shall be kept at their principal place of business and, with all necessary supporting data shall, for the two (2) years next following the end of the
calendar year to which each shall pertain be open for inspection by an independent certified public accountant selected by ABBOTT and reasonably acceptable to MEDIMMUNE upon verifying such
(CONFIDENTIAL TREATMENT REQUESTED) or compliance with this AGREEMENT, but in no event more than once in each calendar year. All information and data offered shall be used only for such purpose. In the
event that such 










inspection shall indicate that in any calendar year the (CONFIDENTIAL TREATMENT REQUESTED) reported as owed and/or paid by MEDIMMUNE are at least five percent (5%) greater than those which were
actually owed and/or paid by MEDIMMUNE, then MEDIMMUNE shall pay the cost of such inspection. All amounts reported as owed and/or paid for (CONFIDENTIAL TREATMENT REQUESTED) which are in excess of the
amounts actually owed and/or paid by MEDIMMUNE on the PRODUCT shall immediately be credited against any and all amounts due and owing by ABBOTT to MEDIMMUNE under this AGREEMENT. 





        3.    EFFECT    



	3.1
	The
DISTRIBUTION AGREEMENT is amended as provided hereinabove as of July 1, 1999 in accordance with Section 14.3 of the DISTRIBUTION AGREEMENT. All other items and
provisions of the DISTRIBUTION AGREEMENT shall be unaffected by this AGREEMENT. 











        IN
WITNESS WHEREOF, the parties have each caused this AGREEMENT to be signed and delivered by its duly authorized officer or representative as indicated below. 



	ABBOTT INTERNATIONAL, LTD	 	MEDIMMUNE, INC.


	

By:	

/s/  WILLIAM G. DEMPSEY      
 William G. Dempsey	
 	

By:	

/s/  MELVIN D. BOOTH      
 Melvin D. Booth
	Name:	William G. Dempsey	 	Name:	Melvin D. Booth
	Title:	Senior Vice President

Abbott International	 	Title:	President





JOINDER  


        The undersigned, Abbott Laboratories, an Illinois Corporation, hereby consents to this AGREEMENT and joins in the execution of this AGREEMENT for the purpose of
obligating itself to the obligations and undertakings of Abbott International Ltd., as set forth in this AGREEMENT. 



	ABBOTT LABORATORIES	 
	

By:	

/s/  WILLIAM G. DEMPSEY      
 Name: William G. Dempsey

Title: Senior Vice President, Abbott International, Abbott Laboratories

Dated:    October 13, 1999	

 











QuickLinks



Exhibit 10.26.2


2nd AMENDMENT TO THE DISTRIBUTION AGREEMENT